Veterinary Medicines

Vanguard DA2PI-CPV Lyofilisaat en oplosmiddel voor suspensie voor injectie

Authorised
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine distemper virus, strain N-CDV, Live
Download as PDF

Product identification

Medicine name:
Vanguard DA2PI-CPV Lyofilisaat en oplosmiddel voor suspensie voor injectie
Vanguard DA2PI-CPV Lyophilisat et solvant pour suspension injectable
Vanguard DA2PI-CPV Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine parvovirus, strain NL-35-D, Live
  • Canine distemper virus, strain N-CDV, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    6.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan, Live
    3.20
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    7.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
  • Canine distemper virus, strain N-CDV, Live
    3.00
    log10 cell culture infective dose 50
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • Vanguard DA2PI-CPV 25 Vials with Lyophilisate and 25 Vials with solvent for suspension for injection
  • Vanguard DA2PI-CPV 100 Vials with Lyophilisate and 100 Vials with solvent for suspension for injection
  • Vanguard DA2PI-CPV 10 Vials with Lyophilisate and 10 Vials with solvent for suspension for injection
  • Vanguard DA2PI-CPV 1 Vial with Lyophilisate and 1 Vial with solvent for suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V161506
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 22/03/2022
Download
French (PDF)
Published on: 22/03/2022
Download
German (PDF)
Published on: 22/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."